Literature DB >> 24972891

Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia.

Nina Lang1, Florian Sterzing, Alexander H Enk, Jessica C Hassel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24972891     DOI： 10.1007/s00066-014-0707-0

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity.

Authors:  Natalia Rompoti; Bastian Schilling; Elisabeth Livingstone; Klaus Griewank; Uwe Hillen; Wolfgang Sauerwein; Christoph Pöttgen; Martin Stuschke; Dirk Schadendorf; Lisa Zimmer
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544

2.  Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.

Authors:  James J Harding; Christopher A Barker; Richard D Carvajal; Jedd D Wolchok; Paul B Chapman; Mario E Lacouture
Journal:  J Clin Oncol       Date:  2014-01-27       Impact factor: 44.544

3.  Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports.

Authors:  B Schulze; M Meissner; M Wolter; C Rödel; C Weiss
Journal:  Strahlenther Onkol       Date:  2013-12-22       Impact factor: 3.621

4.  Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.

Authors:  L Boussemart; E Routier; C Mateus; K Opletalova; G Sebille; N Kamsu-Kom; M Thomas; S Vagner; M Favre; G Tomasic; J Wechsler; L Lacroix; C Robert
Journal:  Ann Oncol       Date:  2013-02-13       Impact factor: 32.976
  4 in total
  5 in total

1.  BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.

Authors:  Panagiotis Mastorakos; Zhiyuan Xu; James Yu; Judith Hess; Jack Qian; Ajay Chatrath; Davis G Taylor; Douglas Kondziolka; Ronald Warnick; Veronica Chiang; Jason Sheehan
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

Review 2.  Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies.

Authors:  Elizabeth Guimond; Chiaojung Jillian Tsai; Ali Hosni; Grainne O'Kane; Jonathan Yang; Aisling Barry
Journal:  Adv Radiat Oncol       Date:  2022-07-14

Review 3.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Authors:  Christopher J Anker; Kenneth F Grossmann; Michael B Atkins; Gita Suneja; Ahmad A Tarhini; John M Kirkwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-01       Impact factor: 7.038

4.  Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John's wort skin oil.

Authors:  Tanja Eichkorn; Fabian Schunn; Sebastian Regnery; Rami El Shafie; Juliane Hörner-Rieber; Sebastian Adeberg; Klaus Herfarth; Jürgen Debus; Laila König
Journal:  Strahlenther Onkol       Date:  2021-01-24       Impact factor: 3.621

5.  Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

Authors:  Markus Hecht; Friedegund Meier; Lisa Zimmer; Bülent Polat; Carmen Loquai; Carsten Weishaupt; Andrea Forschner; Ralf Gutzmer; Jochen S Utikal; Simone M Goldinger; Michael Geier; Jessica C Hassel; Panagiotis Balermpas; Felix Kiecker; Ricarda Rauschenberg; Ursula Dietrich; Patrick Clemens; Carola Berking; Gerhard Grabenbauer; Dirk Schadendorf; Stephan Grabbe; Gerold Schuler; Rainer Fietkau; Luitpold V Distel; Lucie Heinzerling
Journal:  Br J Cancer       Date:  2018-02-13       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.